研究

Fujita K, Matsushita Y, Toyoda S, Kojima T, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Nakamura E, Kaneko T, Kitano G, Motoshima T, Shiraishi, Kira S, Murashima T, Hara H, Matsumura, Nishiyama N, Miyake H, Kitamura H, Uemura H.

The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy

Nishimoto M, Fujita K, Ri A, Fujimoto S, Oguma Y, Toyoda S, Hashimoto M, Kikuchi T, Adomi S, Saito Y, Mori Y, Minami T, Nozawa M, Yoshimura K, Hosono M, Uemura H.

Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 Treatment

Ohzeki T, Kita H, Kunishige R, Hayashi T, Nishioka T, Sugimoto K, Minami T, Fujita K.

Initial experience with robot-assisted adrenalectomy for giant adrenal tumors

Toyoda S, Fukuokaya W, Mori K, Kawada T, Katayama S, Nishimura S, Maenosono R, Tsujino T, Adachi T, Hirasawa Y, Saruta M, Komura K, Nukaya T, Yanagisawa T, Takahara K, Hashimoto T, Azuma H, Ohno Y, Shiroki R, Araki M, Kimura T, Fujita K; JK-FOOT study group.

Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy

Yamamoto Y, Fujimoto S, Hashimoto M, Minami T, Fukuokaya W, Yanagisawa T, Saruta M, Takahara K, Nishimura K, Tsujino T, Nakamori Y, Hashimoto T, Kimura T, Shiroki R, Azuma H, Ohno Y, Fujita K.

Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor

Kura Y, De Velasco MA, Sakai K, Uemura H, Fujita K, Nishio K.

Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer

Wakamori C, De Velasco MA, Sakai K, Kura Y, Matsushita M, Fujimoto S, Hatano K, Nonomura N, Fujita K, Nishio K, Uemura H.

A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk

Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, Saruta M, Takahara K, Fujita K, Minami T, Adachi T, Hirasawa Y, Hashimoto T, Ohno Y, Uemura H, Shiroki R, Azuma H, Kimura T.

Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study

Uchimoto T, Tsuchida S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Hashimoto M, Higashio T, Matsuda T, Nishimura K, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Fujita K, Kimura T, Ohno Y, Shiroki R, Uemura H, Azuma H.

Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors

Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H; Japanese Urological Oncology Group.

Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy

Yoshimura A, Kato T, Nakai Y, Tsujihata M, Toyoda S, Sato M, Matsuzaki K, Nakata W, Takao T, Inoguchi S, Okuda Y, Yamamichi G, Ishizuya Y, Yamamoto Y, Hatano K, Kawashima A, Takada S, Inoue H, Nishimura K, Miyake O, Fujita K, Nakayama M, Nishimura K, Nonomura N.

Clinical outcomes of first-line combination therapy with immune checkpoint inhibitor for metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study in Japan

Nagahara A, Uemura M, Sato M, Nakata W, Tsujihata M, Takao T, Matsumura S, Nishimura K, Takada S, Iwanishi T, Kobayashi Y, Ishizuya Y, Takada T, Okada K, Inoue H, Kato T, Hatano K, Kawashima A, Ujike T, Fujita K, Nonomura N.

Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study

Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, Ito N, Iwamoto H, Kohjimoto Y, Hara I.

Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma

Katayama S, Pradere B, Grossman NC, Potretzke AM, Boorjian SA, Ghoreifi A, Daneshmand S, Djaladat H, Sfakianos JP, Mari A, Khene ZE, D'andrea D, Hayakawa N, Fujita K, Heindenreich A, Raman JD, Roumiguié M, Abdollah F, Breda A, Fontana M, Rouprêt M, Margulis V, Karakiewicz PI, Araki M, Nasu Y, Shariat SF.

Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma

Oka T, Hatano K, Tani M, Yoshimura A, Horibe Y, Liu Y, Sassi N, Okuda Y, Yamamoto A, Uemura T, Yamamichi G, Ishizuya YU, Yamamoto Y, Kato T, Kawashima A, Fujita K, Nonomura N.

PSA Kinetics Affect Prognosis in Patients With Castration-resistant Prostate Cancer Treated With Enzalutamide

Tanaka H, Matsuyama S, Ohta T, Kakazu K, Fujita K, Fukuhara S, Soda T, Miyagawa Y, Tsujimura A.

The Natural HASPIN Inhibitor Coumestrol Suppresses Intestinal Polyp Development, Cachexia, and Hypogonadism in a Mouse Model of Familial Adenomatous Polyposis (ApcMin/+)

Hamamoto S, Tasaki Y, Yamashita S, Furukawa J, Fujita K, Tomida R, Miyake M, Ito N, Iwamoto H, Sugiyama Y, Taguchi K, Yasui T.

External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma

Hashimoto M, Karnup S, Daugherty SL, Cho KJ, Banno E, Shimizu N, Fujita K,Hirayama A, Uemura H, de Groat WC, Beckel JM, Yoshimura N.

Sex differences in lower urinary tract function in mice with or without spinal cord injury.

De Velasco MA, Kura Y, Fujita K, Uemura H.

Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.

Yutaka Yamamoto,Mituhisa Nishimoto, Yasunori Akashi,Keisuke Kiba, Takafumi Minami,Masahiro Nozawa,Kazuhiro Yoshimura,Akihide Hirayama, Hirotsugu Uemura and Kazutoshi Fujita

Impact of Novel Agents on Patient Characteristics,Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer

Taigo Kato,Yuzo Nakano,Fumiya Hongo,Hidenori Katano,Tomoaki MIyagawa,Kosuke Ueda,Haruhito Azuma,Masahiro Nozawa,Nobuyuki Hinata,Junivhi Hori,Taiyo Otoshi,Nobuaki Shimizu,Mana Aizawa,Shingo Osada,Akiko

Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advenced renal cell carcinoma in Japan:A multicenter,retrospective,observational stude(J-DART)

Mamoru Harada,Hitoshi Kotani, Yuichi Iida, Ryosuke Tanino, Takafumi Minami, Yoshihiro Komohara, Kazuhiro Yoshikawa, Hirotsugu Uemura

Hypoxia-related carbonic anhydrase 9 induces serpinB9 expression in cancer cells and apoptosis in T cells via acidosis

Hideaki Miyake,Rikiya Matsumoto,Kiyohide Fujimoto,Atsushi Mizokami,Hirotsugu Uemura,Toshiyuki Kamoto,satoru Kawakami,Kazuyoshi Nakamura,shigekatsu Maekawa,Kazuhiro Shibayama,Aki Watanabe,Miku lto,Yohei Tajima,Hideyasu Matsuyama,Hiroji Uemura

Clinical Outcomes of Patients with High-risk Metastatic Hormone-naive Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study

Simon Chowdhury,Anders Bjartell , Neeraj Agarwal , Byung H Chung , Robert W Given , Andrea J Pereira de Santana Gomes , Axel S Merseburger , Mustafa Özgüroğlu , Áｌvaro Juárez Soto , Hirotsugu Uemura , Ding-Wei Ye , Sabine D Brookman-May  , Anil Londhe , Amitabha Bhaumik , Suneel D Mundle , Julie S Larsen , Sharon A McCarthy , Kim N Chi 

Prostate-specific antigen (PSA) Decline with Apalutamide therapy is Associated with Longer survival and Improved Outcomes in Individuals with Metastatic Prostate Cancer: A plain Language summary of the TITAN Study

Eisuke Tomiyama,Kazutoshi Fujita,Mamoru Hashimoto,Hirotsugu Uemura,Norio Nonomura

Urinary markers for bladder cancer diagnosis: A review of current status and future challenges